leisure time -WSS

leisure time

author：comprehensive 2025-10-02 11:10:21 - browse：1

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Pfizer, Moderna say biotech, pharma drug development is a sprint

entertainment

WSS

Testing GLP

U.K. officials, researchers try to ease path for bespoke genetic treatments

Lab trade group sues FDA to halt regulation of lab

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

With Wegovy coverage, Medicare patients may face high costs

Readout Newsletter: Illumina, CRISPR, Regeneron

focus

leisure time

focus

Drug repurposing or repositioning? The language matters

Latest bird flu infection made farmworker sicker than earlier cases

Novavax promises a turnaround & Lilly roils the obesity market

Medical devices makers are asking for forgiveness, not permission

Drug repurposing or repositioning? The language matters

Pregnancy ages women, but effects reverse after delivery

Hepatitis C has a cure — but many Americans still lack access to it

CRISPR technology availability, affordability needs to be expanded

What does generative AI mean for health care? We asked experts

Do more moles mean more problems? Not so, says new study

knowledge

Pregnancy ages women, but effects reverse after delivery

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

iTeos Therapeutics debuts first data on TIGIT

Chinese researcher claims birth of first gene

Readout LOUD podcast, live from the STAT Breakthrough Summit East

knowledge

knowledge

entertainment

hotspot